0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Ophthalmology Clinical Challenge |

Intractable Graves Ophthalmopathy?—Quiz Case

Francisco Castillo, MD; James A. Garrity, MD; Daniel J. Kravitz, MD
JAMA Ophthalmol. 2013;131(2):269. doi:10.1001/jamaophthalmol.2013.2264a.
Text Size: A A A
Published online

Extract

A 38-year-old, otherwise healthy man presented to the clinic for evaluation of his progressive Graves ophthalmopathy. His diagnosis dated back to 1992 when he was told that he may have hyperthyroidism. No therapy was instituted at the time, and he had never taken antithyroid medications or received radioactive iodine. He was followed up annually by an endocrinologist and had yearly measurements of thyrotropin and thyrotropin-receptor antibodies, which had always been normal. From the ophthalmic standpoint, the right eye became proptotic in 1992 at the same time when he was diagnosed with “hyperthyroidism.” His proptosis was treated with oral steroids and responded promptly to this therapy. In view of his symptoms and prompt resolution with the established therapy, a presumed diagnosis of Graves ophthalmopathy was made. The patient remained asymptomatic for 3 years, at which time he once again noted proptosis, this time in both eyes with the right more prominent than the left. Therapy with steroids was once again instituted and he improved promptly. From this point on, he experienced yearly recurrent proptosis, which was treated with oral steroids each time. Most recently, the episodes became increasingly severe and he experienced recurrent proptosis approximately 3 times a year. A bilateral 2-wall orbital decompression performed at this point provided him with minimal relief from his symptoms for only 6 months before he experienced proptosis again. Since his decompression, the patient had diplopia in primary gaze when he was tired and in extremes of gaze at all times. He presented to our practice for further evaluation. In addition to the earlier-mentioned details (Figure 1), the patient denied any other significant medical history and was not taking any medications at the time of our consultation. He denied tobacco use.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Proptosis and conjunctival hyperemia with no evidence of upper eyelid retraction or eyelid lag.

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Serum Immunoglobulin G4 levels are elevated in patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) Published online Nov 17, 2014.;
Graves' disease after treatment with Alemtuzumab for multiple sclerosis. Hormones (Athens) Published online Nov 5, 2014.;
Jobs
brightcove.createExperiences();